Source: Kapitales ResearchHighlights:

• One company surged more than 34% after receiving a takeover proposal carrying a substantial premium to its previous closing price.
• A major supplier to the building and renovation sector extended its rally with a gain of more than 10%.
• A healthcare technology company advanced after highlighting growth opportunities across its clinical trials business.

Several ASX-listed stocks delivered strong gains during Wednesday's session, with Steadfast Group Limited, Reece Limited, and Cogstate Ltd attracting significant investor attention. A mix of corporate activity, sector momentum and business growth updates drove the advances.Stock Movements:

• Steadfast Group Limited (ASX: SDF) rose 34.43% to AU$5.31
• Reece Limited (ASX: REH) gained 10.04% to AU$15.67
• Cogstate Ltd (ASX: CGS) climbed 8.69% to AU$2.82

Steadfast Jumps on Takeover InterestSteadfast recorded the strongest gain among the trio after revealing it had entered into a process deed with a consortium comprising Amwins Group and Dragoneer Investment Group. The consortium submitted a conditional, non-binding proposal to acquire 100% of Steadfast through a scheme of arrangement at AU$6.00 per share in cash. The offer implies an enterprise value of approximately AU$7.7 billion and represents a premium of about 51.9% to Steadfast's closing price on 9 June 2026. The board stated that it intends to unanimously recommend the transaction if acceptable terms are agreed and subject to customary conditions and approvals.Reece Extends Strong MomentumReece continued its upward trajectory, adding more than 10% during the session. The plumbing and bathroom products supplier remained in focus following investor optimism surrounding the broader consumer and housing-related sectors. The latest advance placed the stock among the day's top performers as investors continued to assess the company's long-term growth prospects and market position.Cogstate Highlights Clinical Trials Growth StrategyCogstate gained ground after hosting an investor webinar focused on expanding its clinical trials business through broader indication coverage and higher-value service offerings. Management highlighted strong FY26 sales contract momentum, diversification beyond Alzheimer's disease into psychiatry, narcolepsy and rare diseases, and increasing adoption of value-added services such as central rating solutions. The company reported US$67.1 million in sales contracts executed during the nine months to 31 March 2026 and outlined initiatives aimed at supporting sustained growth into FY27 and beyond.Market TakeawayThe sharp gains recorded by Steadfast, Reece and Cogstate demonstrate how investors continue to respond strongly to corporate transactions, growth initiatives and sector-specific opportunities. While Steadfast benefited from takeover interest, Reece attracted continued buying momentum and Cogstate gained support from its expanding clinical trials strategy, helping all three stocks stand out on the ASX.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au